Gain Therapeutics (NASDAQ:GANX) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Key Points

• Gain Therapeutics beat earnings expectations, reporting a quarterly loss of $0.11 per share versus the consensus estimate of a $0.14 loss.
• Shares rose to $1.92 in Tuesday trading, while the company maintained a modest $81.76 million market capitalization and strong liquidity, with current and quick ratios of 4.69.
• Analyst sentiment remains generally positive, with five Buy ratings and one Sell rating producing a “Moderate Buy” consensus and an average price target of $7.50; institutional investors own 11.97% of the stock.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.03, Zacks reports.

Gain Therapeutics Stock Performance

Shares of NASDAQ:GANX traded up $0.15 during trading on Tuesday, reaching $1.92. The company had a trading volume of 159,283 shares, compared to its average volume of 794,695. The firm has a market capitalization of $81.76 million, a price-to-earnings ratio of -3.31 and a beta of 0.19. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.69 and a quick ratio of 4.69. The stock's fifty day moving average price is $1.78 and its 200 day moving average price is $1.93. Gain Therapeutics has a fifty-two week low of $1.46 and a fifty-two week high of $4.34.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. BTIG Research reiterated a "buy" rating and set a $5.00 price objective on shares of Gain Therapeutics in a research report on Tuesday, June 30th. Oppenheimer reissued an "outperform" rating on shares of Gain Therapeutics in a research report on Wednesday, May 27th. HC Wainwright reaffirmed a "buy" rating and issued a $8.00 price target on shares of Gain Therapeutics in a research report on Wednesday, July 1st. Roth Capital reiterated a "buy" rating on shares of Gain Therapeutics in a research note on Tuesday, May 12th. Finally, Weiss Ratings cut Gain Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, June 9th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Gain Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $7.50.

Hedge Funds Weigh In On Gain Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Sprott Inc. acquired a new position in Gain Therapeutics in the 4th quarter valued at $39,000. Commonwealth Equity Services LLC acquired a new stake in shares of Gain Therapeutics in the 4th quarter worth $41,000. Millennium Management LLC purchased a new stake in shares of Gain Therapeutics in the fourth quarter valued at about $45,000. JPMorgan Chase & Co. purchased a new stake in shares of Gain Therapeutics in the third quarter valued at about $47,000. Finally, Engineers Gate Manager LP acquired a new position in shares of Gain Therapeutics during the fourth quarter worth about $47,000. 11.97% of the stock is currently owned by hedge funds and other institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc NASDAQ: GANX is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain's lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source